Navigation Links
ALS TDI and Asklepios to Develop New Therapeutic Delivery Options for Treating Lou Gehrig's Disease
Date:1/20/2009

Collaboration to evaluate gene delivery vectors for ALS

CAMBRIDGE, Mass. and CHAPEL HILL, N.C., Jan. 20 /PRNewswire-USNewswire/ -- ALS Therapy Development Institute (ALS TDI) and Asklepios BioPharmaceutical, Inc. announced today their collaboration aimed at developing a panel of viral vectors that could be used to deliver therapeutics based on targets identified by ALS TDI that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). The collaboration between the two research centers will focus on screening and characterization of optimal delivery vectors.

"This project is an aggressive and proactive effort to develop the safest alternative therapeutic delivery options available today," reported Dr. Steve Perrin, Chief Scientific Officer at ALS TDI after a recent conference call with more than 140 members of the ALS community. "By focusing on developing therapeutic strategies while operating the largest discovery biology program for this disease, we are preparing to rapidly move potential therapeutics through the drug development process with today's patients in mind."

The custom constructed Biological Nano Particle (BNP) vectors are designed using proprietary technology developed by Asklepios. ALS TDI will evaluate the BNP vectors in a tightly-managed mouse colony that is based on mutations in a specific mutated protein, which is a cause of a genetic form of disease. BNP vectors are of interest to drug development scientists because they generally do not elicit as aggressive an immune response often associated with other viruses, and have been clinically tested. Samples from animals treated with BNP vectors will be analyzed by a variety of molecular and immunohistochemistry analysis techniques at ALS TDI to determine in which cell types each vector becomes localized in various tissue samples. This project is seen as bolstering tools available as part of a key therapeutic strategy used by ALS TDI to develop effective therapeutics for ALS: viral gene therapy.

"There is a consensus that gene therapeutics are ideally suited to target the largely unmet medical needs of a variety of orphan diseases including ALS. I'm excited that AskBio has formed a partnership with ALS TDI, as it combines our experience in developing gene delivery technology with the expertise and capabilities that ALS TDI have in screening ALS therapeutic leads. Our main objective is to resolve issues that have limited successful gene delivery approaches to ALS in the past, and I look forward with a great deal of optimism to offering this initial step toward progress for the ALS community," said Jude Samulski, Ph.D., President and Founder of Asklepios BioPharmaceutical, Inc.

Funding for this project is made possible as part of a major, three-year, $18 million funding and scientific collaboration between ALS TDI and with the Muscular Dystrophy Association (MDA) and its Augie's Quest Initiative, entered into at the beginning of 2007. Asklepios BioPharmaceutical, Inc. also receives funding from MDA.

About the ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) (www.als.net), based in Cambridge, Massachusetts, operates the world's largest research and development program focused exclusively on ALS. The Institute has a staff of more than 30 scientists and research technicians, working on behalf of ALS patients to discover and advance therapeutics for treating, and ultimately curing, ALS. The nonprofit biotechnology institute excels in identifying novel disease targets, discovering compounds that may act against these targets, and screening potential treatments for clinical development.

About Asklepios BioPharmaceutical, Inc.

AskBio is a private clinical-stage biotechnology company engaged in the development of novel, gene therapy mediated protein therapies using a proprietary Biological Nano Particle ("BNP(TM)") technology platform. BNPs may be used to deliver a broad variety of biological material to a cell, including therapeutic genes, monoclonal antibodies, RNAi, and vaccines, among others. The company's mature intellectual property portfolio is the result of over $35 million in grants and other funding and is based on the scientific work of Professor R. Jude Samulski & colleagues at the University of North Carolina at Chapel Hill. The company is currently engaged in multiple gene therapy based therapeutic programs. For additional information, visit AskBio's web site at http://www.askbio.com

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (http://www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About MDA

MDA (www.mda.org) is the world's largest provider of ALS services and funder of ALS research. Over the years, it has expended $230 million in this effort. It operated 225 clinics across the county, 38 of which are ALS-specific research and care centers.

Media Contact: Robert Goldstein, ALS TDI, 617-441-7295, rgoldstein@als.net

Luke Roberts, Asklepios BioPharmaceutical Inc,

919-968-2727, lroberts@askbio.com


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Collexis Healthcare to Expand Capabilities for Asklepios Group Utilizing Microsoft Solutions
2. Scientists Develop Natural Protection for Stored Foods
3. Isolation of a new gene family essential for early development
4. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
5. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
6. Smokers More Likely to Develop Dementia
7. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
8. Ovation further advances development pipeline with new phase III epilepsy study
9. Researchers develop long-lasting growth hormone
10. Pioneer Surgical Technology Hires Vice President of New Business Development
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: